UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 4, 2020
Clovis Oncology, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-35347 |
90-0475355 |
||
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
5500 Flatiron Parkway, Suite 100
|
|
|
(Address of principal
|
(Zip Code) |
Registrant’s telephone number, including area code: (303) 625-5000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
||
Common Stock par Value $0.001 per Share |
CLVS |
The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 4, 2020, the stockholders of Clovis Oncology, Inc. (the “Company”) approved and adopted the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) at the Company’s Annual Meeting of Stockholders. Additional information regarding the results of the Annual Meeting is set forth below under Item 5.07. Under the 2020 Plan, subject to adjustment for certain changes in capitalization or other corporate events, the Company is authorized to issue up to 6,470,000 shares of common stock pursuant to equity-based awards, which may be granted to eligible participants in furtherance of the Company’s broader compensation strategy and philosophy. Awards granted under the 2020 Plan will be granted upon terms approved by the Company’s Compensation Committee of the Board of Directors and set forth in an award agreement or other evidence of an award. The 2020 Plan is described in greater detail in the Company’s proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 24, 2020, under the caption “Approval of the Clovis Oncology, Inc. 2020 Stock Incentive Plan,” which disclosure is incorporated herein by reference. The description of the 2020 Plan contained in such proxy statement is qualified in its entirety by reference to the full text of the 2020 Plan, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference. The forms of the 2020 Plan Option Grant Notice and Agreement and the 2020 Plan Restricted Stock Unit Grant Notice and Agreement are attached hereto as Exhibits 10.2 and 10.3, respectively.
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
The Annual Meeting of Stockholders of the Company was held on June 4, 2020. At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast their votes as described below.
Proposal One
The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company’s Board of Directors.
|
For |
Withheld |
Broker Non-Votes |
|||||||||
Keith Flaherty |
13,221,980 |
2,184,374 |
37,101,715 |
|||||||||
Ginger Graham |
13,586,732 |
1,819,622 |
37,101,715 |
|||||||||
Edward J. McKinley |
13,565,580 |
1,840,774 |
37,101,715 |
Proposal Two
Proposal two was to hold an advisory vote on the compensation of the Company’s named executive officers, as described in the proxy materials. This proposal was approved.
For |
Against |
Abstained |
Broker Non-Votes |
|||
11,521,592 |
2,882,630 |
1,002,132 |
37,101,715 |
Proposal Three
Proposal three was to ratify the appointment of Ernst & Young LLP as auditors of the Company for the fiscal year ending December 31, 2020, as described in the proxy materials. This proposal was approved.
For |
Against |
Abstained |
Broker Non-Votes |
|||
48,453,535 |
3,601,738 |
452,796 |
— |
Proposal Four
Proposal four was to approve the Clovis Oncology, Inc. 2020 Stock Incentive Plan, as described in the proxy materials. This proposal was approved.
For |
Against |
Abstained |
Broker Non-Votes |
|||
11,749,765 |
3,419,734 |
236,855 |
37,101,715 |
2
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
10.1 |
||||
10.2 |
Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan — Option Grant Notice and Agreement. |
|||
10.3 |
||||
104 |
Cover Page Interactive Data File (formatted as Inline XBRL). |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Clovis Oncology, Inc.
|
|||
June 4, 2020 |
By: |
/s/ Paul Gross |
||
|
Name: |
Paul Gross |
||
|
Title: |
Executive Vice President and General Counsel |
4
Exhibit 10.2
OPTION GRANT NOTICE AND AGREEMENT
Clovis Oncology, Inc. (the Company), pursuant to its 2020 Stock Incentive Plan (the Plan), hereby grants to the Holder the number of Options set forth below, each Option representing the right to purchase one share of Stock at the applicable Exercise Price (set forth below). The Options are subject to all of the terms and conditions set forth in this Option Grant Notice and Agreement (this Agreement) as well as all of the terms and conditions of the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the same meaning as set forth in the Plan.
Holder: |
[ ] |
|
Date of Grant: |
[ ] |
|
Vesting Commencement Date: |
[ ] |
|
Number of Options: |
[ ] |
|
Exercise Price: |
$[ ] |
|
Expiration Date: |
[ ] |
|
Type of Option: |
Nonqualified Stock Option |
Vesting Schedule: |
[ ]
Notwithstanding the foregoing, in the event that the Holder experiences a Termination by the Service Recipient without Cause [or by the Holder for Good Reason (as defined in the Holders Participant Agreement)] within twenty-four (24) months following a Change in Control of the Company, all of the Holders unvested Options shall vest in full upon such Termination. |
|
Exercise of Options: | To exercise a vested Option, the Holder (or his or her authorized representative) must give written notice to the Company, using the form of Option Exercise Notice attached hereto as Exhibit A, stating the number of Options which Holder intends to exercise. The Company will issue the shares of Stock with respect to which the Options are exercised upon payment of the shares of Stock acquired in accordance with Section 5(d) of the Plan, which Section 5(d) is incorporated herein by reference and made a part hereof. For the avoidance of doubt, all unvested Options that do not vest upon the occurrence of a Termination shall be forfeited for no consideration as of the date of such Termination. |
Upon exercise of Options the Holder will be required to satisfy applicable withholding tax obligations as provided in Section 16 of the Plan. | ||
Termination: | Except as otherwise provided in the Vesting Schedule paragraph above with respect to the treatment of Holders Restricted Stock Units upon certain Terminations, Section 5(f) of the Plan regarding treatment of Options upon Termination is incorporated herein by reference and made a part hereof. | |
Additional Terms: |
Options shall be subject to the following additional terms:
Options shall be exercisable in whole shares of Stock only.
Each Option shall cease to be exercisable as to any share of Stock when the Holder purchases the share of Stock or when the Option otherwise expires or is forfeited.
Any certificates representing the Stock delivered to the Holder shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such shares are listed, and any applicable federal or state laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions as the Committee deems appropriate.
This Agreement does not confer upon the Holder any right to continue as an employee or service provider of the Company or any other member of the Company Group.
This Agreement shall be construed and interpreted in accordance with the laws of the State of Colorado, without regard to the principles of conflicts of law thereof.
The Holder agrees that the Company may deliver by email all documents relating to the Plan or these Options (including, without limitation, a copy of the Plan) and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the Securities and Exchange Commission). The Holder also agrees that the Company may deliver these documents by posting them on a website maintained by the Company or by a third party under contract with the Company. If the Company posts these documents on a website, it shall notify the Holder by email or such other reasonable manner as then determined by the Company. |
-2-
This Agreement, together with the Plan, constitutes the entire understanding and agreement of the parties hereto and supersedes all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the Company and Holder relating to the subject matter hereof. |
* * *
-3-
THE UNDERSIGNED HOLDER ACKNOWLEDGES RECEIPT OF THE PLAN, AND, AS AN EXPRESS CONDITION TO THE GRANT OF OPTIONS UNDER THIS AGREEMENT, AGREES TO BE BOUND BY THE TERMS OF BOTH THE AGREEMENT AND THE PLAN.
CLOVIS ONCOLOGY, INC. |
HOLDER |
|
BY: |
||
Signature |
Signature |
|
Name: Paul E. Gross
Title: Executive Vice President, General Counsel and Chief Compliance Officer |
Name: [ ]
DATE: |
|
Date: |
-4-
, 20
Clovis Oncology, Inc.
[Address]
Attn: [ ]
Re: Notice of Exercise
1. |
By delivery of this Notice of Exercise, I am irrevocably electing to exercise options to purchase shares of Common Stock, par value $ per share (Shares) of Clovis Oncology, Inc. (the Company) granted to me under the Companys 2020 Stock Incentive Plan (the Plan). |
2. |
The number of Shares I wish to purchase by exercising my options is . |
3. |
The applicable purchase price (or exercise price) is $ per Share, resulting in an aggregate purchase price of $ (the Aggregate Purchase Price). |
4. |
I am satisfying my obligation to pay the Aggregate Purchase Price by: |
☐ |
Delivering to the Company, with this Notice of Exercise, an amount equal to the Aggregate Purchase Price in immediately available United States dollars, or by certified or bank cashiers check. |
☐ |
Delivering to the Company, with this Notice of Exercise, Shares having a value equal to the Aggregate Purchase Price. |
☐ |
Delivering an irrevocable direction to a securities broker (on a form prescribed by the Committee) to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the Aggregate Purchase Price. I have attached to this Notice of Exercise the written communication confirming the consent of the Committee to my use of the cashless exercise procedure described herein. |
☐ |
Authorizing the Company, through this Notice of Exercise, to effectuate a net exercise, pursuant to which I will receive the number of Shares exercised (as set forth in paragraph 2 above), reduced by the number of Shares equal to the Aggregate Purchase Price divided by the fair market value per Share on the date of exercise. I have attached to this Notice of Exercise the written communication confirming the consent of the Committee to my use of the net exercise procedure described herein. |
5. |
To satisfy the applicable withholding taxes: |
☐ |
I have enclosed an amount equal to the applicable withholding taxes in immediately available United States dollars, or by certified or bank cashiers check. |
-5-
☐ |
I elect to have such amount satisfied by delivery of an irrevocable direction to a securities broker (on a form prescribed by the Committee) to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the applicable withholding taxes. I have attached to this Notice of Exercise the written communication confirming the consent of the Committee to my use of the cashless exercise procedure described herein. |
☐ |
I elect to have such amount satisfied by the use of Shares such that the number of Shares I receive upon exercise will be reduced (or further reduced if net exercise was chosen above) by a number of Shares with an aggregate fair market value on the date of exercise equal to any federal, state or local income or other taxes required by law to be withheld by the Company. I have attached to this Notice of Exercise the written communication confirming the consent of the Committee to my use of the withholding tax procedure described herein. |
6. |
I hereby agree to be bound by all of the terms and conditions set forth in the Plan and any award agreement to which the options were granted under. If I am not the person to whom the options were granted by the Company, proof of my right to purchase the Shares of the Company is enclosed. |
7. |
I have been advised to consult with any legal, tax or financial advisors I have chosen in connection with the purchase of the Shares. |
Dated:
* | ||||
(Optionees signature) | (Additional signature, if necessary) | |||
(Print name) | (Print name) |
(Full address) | (Full address) |
* |
Each person in whose name Shares are to be registered must sign this Notice of Exercise. (If more than one name is listed, specify whether the owners will hold the Shares as community property or as joint tenants with the right of survivorship). |
-6-
Exhibit 10.3
RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT
Clovis Oncology, Inc. (the Company), pursuant to its 2020 Stock Incentive Plan (the Plan), hereby grants to the Holder the number of Restricted Stock Units set forth below, each Restricted Stock Unit being a notional unit representing the right to receive one share of Stock. The Restricted Stock Units are subject to all of the terms and conditions set forth in this Restricted Stock Unit Grant Notice and Agreement (this Agreement) as well as all of the terms and conditions of the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the same meaning as set forth in the Plan.
Holder: |
[______________] | |
Date of Grant: |
[______________] | |
Number of Restricted Stock Units: |
[______________] |
Vesting Schedule: |
[______________] |
Notwithstanding the foregoing, in the event that the Holder experiences a Termination by the Service Recipient without Cause [or by the Holder for Good Reason (as defined in the Holders Participant Agreement)] within twenty-four (24) months following a Change in Control of the Company, all of the Holders unvested Restricted Stock Units shall vest in full upon such Termination. |
Settlement: |
The Company shall settle each vested Restricted Stock Unit for one share of Stock, to be delivered to the Holder as soon as practicable (and in no event later than the date that is two and one-half (21⁄2) months following the last day of the fiscal year in which the applicable vesting date occurs) following the applicable vesting date. |
Termination: |
Except as otherwise provided in the Vesting Schedule paragraph above with respect to the treatment of Holders Restricted Stock Units upon certain Terminations, Section 7(d) of the Plan regarding treatment of Restricted Stock Units upon Termination is incorporated herein by reference and made a part hereof. For the avoidance of doubt, all unvested Restricted Stock Units that do not vest upon the occurrence of a Termination shall be forfeited for no consideration as of the date of such Termination. |
Additional Terms: |
Restricted Stock Units shall be subject to the following additional terms: |
|
The Holder will be required to satisfy applicable withholding tax obligations as provided in Section 16 of the Plan. By signing below, the Holder elects to have such |
-1-
amount satisfied by delivery of an irrevocable direction to a securities broker (on a form prescribed by the Committee) to sell shares of Stock and to deliver all or part of the sale proceeds to the Company in payment of the applicable withholding taxes. The Holder acknowledges and agrees that the Holder does not have authority, influence or control over any sales of Stock effected pursuant to the foregoing, and will not attempt to exercise any authority, influence or control over such sales. It is the intent of the parties that these provisions comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and these provisions shall be interpreted to comply with the requirements of Rule 10b5-1(c). The Holder agrees to make all filings, if any, required under and monitor Holders own compliance with Sections 13(d), 13(g) and 16 of the Exchange Act. |
|
Any certificates representing the Stock delivered to the Holder shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such shares are listed, and any applicable federal or state laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions as the Committee deems appropriate. |
|
This Agreement does not confer upon the Holder any right to continue as an employee or service provider of the Company or any other member of the Company Group. |
|
This Agreement does not confer upon the Holder any voting rights or other rights as a stockholder of the Company unless and until the shares of Stock in respect of the Restricted Stock Units have been issued in settlement thereof. |
|
This Agreement shall be construed and interpreted in accordance with the laws of the State of Colorado, without regard to the principles of conflicts of law thereof. |
|
The Holder agrees that the Company may deliver all documents relating to the Plan or these Restricted Stock Units (including, without limitation, a copy of the Plan) and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the Securities and |
- 2 -
Exchange Commission) by email or by posting them on a website maintained by the Company or by a third party under contract with the Company (with notification of the same to be provided to the Holder by email or such other reasonable manner as determined by the Company). |
|
This Agreement, together with the Plan, constitutes the entire understanding and agreement of the parties hereto and supersedes all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the Company and Holder relating to the subject matter hereof. |
* * *
THE UNDERSIGNED HOLDER ACKNOWLEDGES RECEIPT OF THE PLAN, AND, AS AN EXPRESS CONDITION TO THE GRANT OF RESTRICTED STOCK UNITS UNDER THIS AGREEMENT, AGREES TO BE BOUND BY THE TERMS OF BOTH THE AGREEMENT AND THE PLAN.
CLOVIS ONCOLOGY, INC. | HOLDER | |||||||
By: | ||||||||
Signature | Signature | |||||||
Title: |
|
Date: |
|
|||||
Date: |
|
- 3 -